Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment.

ABSTRACT: Targeted therapies against components of the mitogen-activated protein kinase (MAPK) pathway and immunotherapies, which block immune checkpoints, have shown important clinical benefits in melanoma patients. However, most patients develop resistance, with consequent disease relapse. Therefore, there is a need to identify novel therapeutic approaches for patients who are resistant or do not respond to the current targeted and immune therapies. Melanoma is characterized by homologous recombination (HR) and DNA damage response (DDR) gene mutations and by high replicative stress, which increase the endogenous DNA damage, leading to the activation of DDR. In this review, we will discuss the current experimental evidence on how DDR can be exploited therapeutically in melanoma. Specifically, we wi

SUBMITTER: Maresca L 

PROVIDER: S-EPMC9099918 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature